Retrieve available abstracts of 44 articles: HTML format
Single Articles
June 2025
WANG JH, Sherry AD, Bazyar S, Sutera P, et al Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic
Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II
Randomized Trial.
J Clin Oncol. 2025;43:2059-2068. PubMedAbstract available
STEIN MN, Vinceneux A, Robbrecht D, Doger B, et al Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human
Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1
Study.
J Clin Oncol. 2025 Jun 1:101200JCO2500678. doi: 10.1200/JCO-25-00678. PubMedAbstract available
May 2025
HASSANZADEH C, Kuban D, Pasyar S, Bassett R, et al Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated
Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III,
Prospective, Randomized Controlled Trial.
J Clin Oncol. 2025 May 14:JCO2402057. doi: 10.1200/JCO-24-02057. PubMedAbstract available
GARJE R, Riaz IB, Naqvi SAA, Rumble RB, et al Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate
Cancer: ASCO Guideline Update.
J Clin Oncol. 2025 May 2:JCO2500007. doi: 10.1200/JCO-25-00007. PubMedAbstract available
April 2025
KUNZ N, Kemper C Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as
Prostate Cancer Treatment.
J Clin Oncol. 2025 Apr 22:JCO2500457. doi: 10.1200/JCO-25-00457. PubMed
ARMSTRONG AJ, Liu VYT, Selvaraju RR, Chen E, et al Development and Validation of an Artificial Intelligence Digital Pathology
Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in
Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
J Clin Oncol. 2025 Apr 16:JCO2400365. doi: 10.1200/JCO.24.00365. PubMedAbstract available
March 2025
AGGARWAL RR, Vuky J, VanderWeele D, Rettig M, et al Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating
Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic
Castration-Resistant Prostate Cancer.
J Clin Oncol. 2025 Mar 26:JCO2401989. doi: 10.1200/JCO-24-01989. PubMedAbstract available
SLOVIN SF Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer:
Where Are We Going, What Are We Doing, and Why?
J Clin Oncol. 2025 Mar 13:JCO2402402. doi: 10.1200/JCO-24-02402. PubMed
PETRYLAK DP, Ratta R, Matsubara N, Korbenfeld E, et al Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic
Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III
KEYNOTE-921 Trial.
J Clin Oncol. 2025 Mar 5:JCO2401283. doi: 10.1200/JCO-24-01283. PubMedAbstract available
January 2025
SAAD F, Vjaters E, Testa I, Haresh KP, et al Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
J Clin Oncol. 2025 Jan 17:JCO2402742. doi: 10.1200/JCO-24-02742. PubMed
MITTAL A, Linford G, Gyawali B Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
J Clin Oncol. 2025 Jan 17:JCO2402314. doi: 10.1200/JCO-24-02314. PubMed
YU EY, Rumble RB, Agarwal N, Cheng HH, et al Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO
Guideline.
J Clin Oncol. 2025 Jan 9:JCO2402608. doi: 10.1200/JCO-24-02608. PubMedAbstract available
December 2024
DIZMAN N, Necchi A Promises and Challenges of Dietary Intervention in Patients With Prostate Cancer:
Lessons Learned From the CAPFISH-3 Trial.
J Clin Oncol. 2024 Dec 13:JCO2402444. doi: 10.1200/JCO-24-02444. PubMed
ARONSON WJ, Grogan T, Liang P, Jardack P, et al High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on
Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.
J Clin Oncol. 2024 Dec 13:JCO2400608. doi: 10.1200/JCO.24.00608. PubMedAbstract available
October 2024
BROOKS JD Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to
Reduce Harm and Improve Equity.
J Clin Oncol. 2024 Oct 3:JCO2400941. doi: 10.1200/JCO.24.00941. PubMed
September 2024
MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al Improving Assessment of Radiorecurrent Prostate Cancer: Implications for Salvage
Reirradiation.
J Clin Oncol. 2024 Sep 17:JCO2401067. doi: 10.1200/JCO.24.01067. PubMed
SAAD F, Vjaters E, Shore N, Olmos D, et al Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With
Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
J Clin Oncol. 2024 Sep 16:JCO2401798. doi: 10.1200/JCO-24-01798. PubMedAbstract available
TOMBAL B, Giannarini G Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do
Not EMBARK on When, If the Answer Is How.
J Clin Oncol. 2024 Sep 6:JCO2401134. doi: 10.1200/JCO.24.01134. PubMed
July 2024
VIGNESWARAN HT, Eklund M, Discacciati A, Nordstrom T, et al Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A
Prospective Multicentered Trial.
J Clin Oncol. 2024 Jul 22:JCO2400152. doi: 10.1200/JCO.24.00152. PubMedAbstract available
June 2024
GARCIA JA, Spratt DE Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate
End Point in Metastatic Hormone-Sensitive Prostate Cancer?
J Clin Oncol. 2024 Jun 14:JCO2400210. doi: 10.1200/JCO.24.00210. PubMed
May 2024
LEE WR, Dignam JJ, Amin MB, Bruner DW, et al Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III
Noninferiority Study Comparing Two Fractionation Schedules in Patients With
Low-Risk Prostate Cancer.
J Clin Oncol. 2024 May 17:JCO2302445. doi: 10.1200/JCO.23.02445. PubMedAbstract available
EINSTEIN DJ, Regan MM, Stevens JS, McDermott DF, et al Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically
Recurrent Prostate Cancer: The EMBARK Trial.
J Clin Oncol. 2024 May 16:JCO2400279. doi: 10.1200/JCO.24.00279. PubMedAbstract available
SPRATT DE Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is
It Prognostic or Predictive?
J Clin Oncol. 2024 May 14:JCO2302689. doi: 10.1200/JCO.23.02689. PubMed
SAYAN M, Chen MH, Loffredo M, McMahon E, et al Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients
With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
J Clin Oncol. 2024 May 1:JCO2302394. doi: 10.1200/JCO.23.02394. PubMedAbstract available
April 2024
EKANGER C, Helle SI, Reisaeter L, Hysing LB, et al Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a
Prospective Study With 7.2 Years of Follow-Up.
J Clin Oncol. 2024 Apr 23:JCO2301391. doi: 10.1200/JCO.23.01391. PubMedAbstract available
Erratum: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health
Professionals Follow-Up Study.
J Clin Oncol. 2024 Apr 16:JCO2400454. doi: 10.1200/JCO.24.00454. PubMed
March 2024
YU JB, DeStephano DM, Jeffers B, Horowitz DP, et al Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for
Prostate Cancer.
J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604. PubMedAbstract available
MADAN RA, Yu EY, Posadas EM, Lee RJ, et al Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic
Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
J Clin Oncol. 2024 Mar 15:JCO2302727. doi: 10.1200/JCO.23.02727. PubMedAbstract available
FALLAH J, Xu J, Weinstock C, Gao X, et al Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in
Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant
Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
J Clin Oncol. 2024 Mar 14:JCO2302105. doi: 10.1200/JCO.23.02105. PubMedAbstract available
KWAK L, Ravi P, Armstrong JG, Beckendorf V, et al Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in
Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized
Trials.
J Clin Oncol. 2024 Mar 12:JCO2300762. doi: 10.1200/JCO.23.00762. PubMedAbstract available
HEISS BL, Chang E, Gao X, Truong T, et al US Food and Drug Administration Approval Summary: Talazoparib in Combination With
Enzalutamide for Treatment of Patients With Homologous Recombination Repair
Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol. 2024 Mar 7:JCO2302182. doi: 10.1200/JCO.23.02182. PubMedAbstract available
January 2024
AGGARWAL R, Heller G, Hillman DW, Xiao H, et al PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in
Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate
Cancer (AFT-19).
J Clin Oncol. 2024 Jan 23:JCO2301157. doi: 10.1200/JCO.23.01157. PubMedAbstract available
CHILDS DS, Orme JJ, Ravi P Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent
Prostate Cancer: Is It Clinically Meaningful?
J Clin Oncol. 2024 Jan 23:JCO2302410. doi: 10.1200/JCO.23.02410. PubMed
HALABI S, Roy A, Rydzewska L, Guo S, et al Radiographic Progression-Free Survival and Clinical Progression-Free Survival as
Potential Surrogates for Overall Survival in Men With Metastatic
Hormone-Sensitive Prostate Cancer.
J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535. PubMedAbstract available
DENMEADE SR Resolute Progress Down a Long and Winding Road Leads to the Promised Land of
Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
J Clin Oncol. 2024 Jan 5:JCO2302310. doi: 10.1200/JCO.23.02310. PubMed
December 2023
FALLAH J, Xu J, Weinstock C, Brave MH, et al FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of
Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
J Clin Oncol. 2023 Dec 21:JCO2301868. doi: 10.1200/JCO.23.01868. PubMedAbstract available
November 2023
MATEO J, de Bono JS, Fizazi K, Saad F, et al Olaparib for the Treatment of Patients With Metastatic Castration-Resistant
Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339. PubMedAbstract available
ROY S, Romero T, Michalski JM, Feng FY, et al Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for
Adenocarcinoma of the Prostate.
J Clin Oncol. 2023;41:5005-5014. PubMedAbstract available
GARJE R, Rumble RB, Parikh RA Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic
Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
J Clin Oncol. 2023 Nov 6:JCO2302128. doi: 10.1200/JCO.23.02128. PubMedAbstract available
TAGAWA ST, Thomas C, Sartor AO, Sun M, et al Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery
for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation
Study of (225)Ac-J591.
J Clin Oncol. 2023 Nov 3:JCO2300573. doi: 10.1200/JCO.23.00573. PubMedAbstract available
October 2023
GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al Disparities With Systemic Therapies for Black Men Having Advanced Prostate
Cancer: Where Do We Stand?
J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949. PubMedAbstract available
MADAN RA, Karzai F, VanderWeele DJ, Cheng HH, et al Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic
Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
J Clin Oncol. 2023 Oct 17:JCO2301502. doi: 10.1200/JCO.23.01502. PubMed
September 2023
FRANCOLINI G, Gaetano Allegra A, Detti B, Di Cataldo V, et al Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected
by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II
Trial (ARTO).
J Clin Oncol. 2023 Sep 21:JCO2300985. doi: 10.1200/JCO.23.00985. PubMedAbstract available
STAR J, Bandi P, Siegel RL, Han X, et al Cancer Screening in the United States During the Second Year of the COVID-19
Pandemic.
J Clin Oncol. 2023;41:4352-4359. PubMedAbstract available